Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 13Unknown 3Terminated 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3NSCLC 2Skin Squamous Cell Cancer 1Recurrence 1Brain Neoplasms 1

Interventions

Carboplatin 84Cisplatin 79Pemetrexed 72Docetaxel 62Drug Therapy 44Gemcitabine 43Erlotinib Hydrochloride 42Gefitinib 38Radiotherapy 36Paclitaxel 36pembrolizumab 31Bevacizumab 29icotinib 28osimertinib 27anlotinib 26Nivolumab 26camrelizumab 23Vinorelbine 23Radiosurgery 20aumolertinib 18atezolizumab 17sintilimab 16apatinib 16Endostatins 16endostar protein 15durvalumab 14Surgical Procedures, Operative 13Immunotherapy 13Immune Checkpoint Inhibitors 12Blood Specimen Collection 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Non-Small-Cell Lung × dacomitinib × Clear all
NCT04768491 2021-02-24

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Peking Union Medical College

Unknown
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04675008 2021-01-05

Central Nervous System(CNS) Efficacy of Dacomitinib

Samsung Medical Center

Phase 2 Unknown
30 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04339829 2020-04-09

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Guangdong Association of Clinical Trials

Phase 2 Unknown
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡